Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-12

AUTHORS

Ulrich Kintscher, Peter Bramlage, W Dieter Paar, Martin Thoenes, Thomas Unger

ABSTRACT

OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. RESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. MAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. CONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile. More... »

PAGES

12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1475-2840-6-12

DOI

http://dx.doi.org/10.1186/1475-2840-6-12

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040398603

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17407587


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abdominal Fat", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, HDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fasting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrochlorothiazide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triglycerides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kintscher", 
        "givenName": "Ulrich", 
        "id": "sg:person.0636477725.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636477725.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "TU Dresden", 
          "id": "https://www.grid.ac/institutes/grid.4488.0", 
          "name": [
            "Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bramlage", 
        "givenName": "Peter", 
        "id": "sg:person.01304431360.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304431360.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420214.1", 
          "name": [
            "Sanofi-Aventis Deutschland GmbH, Medical Affairs CardioVascularThrombosis, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paar", 
        "givenName": "W Dieter", 
        "id": "sg:person.01220266165.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220266165.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi-Aventis, Medical Affairs, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thoenes", 
        "givenName": "Martin", 
        "id": "sg:person.01205715672.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205715672.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Unger", 
        "givenName": "Thomas", 
        "id": "sg:person.0752125516.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752125516.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250051268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001153018", 
          "https://doi.org/10.1007/s001250051268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001153018", 
          "https://doi.org/10.1007/s001250051268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-200406000-00024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002454474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-200406000-00024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002454474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200020010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004560003", 
          "https://doi.org/10.2165/00044011-200020010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200020010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004560003", 
          "https://doi.org/10.2165/00044011-200020010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000123072.34629.57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005277791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000123072.34629.57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005277791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.24.4.683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005367642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-6175.2004.04720.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008782891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.26.3.575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009237000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.21.2709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009474275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000080897.52664.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010001455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199200441-00013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010937770", 
          "https://doi.org/10.2165/00003495-199200441-00013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1262-3636(07)70067-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014292627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.23.2981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016077891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3317/jraas.2003.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018201506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3317/jraas.2003.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018201506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2840-4-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018238203", 
          "https://doi.org/10.1186/1475-2840-4-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00038-004-3063-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022661411", 
          "https://doi.org/10.1007/s00038-004-3063-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000127955.36250.65", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029448060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000133732.24501.9e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030294418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000133732.24501.9e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030294418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.105.169404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030755840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000141736.76561.78", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032387441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.nutr.23.011702.073212", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033009996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000215181.60228.f7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038043341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000215181.60228.f7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038043341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.nutr.22.010402.102808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038789731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1373/clinchem.2006.067397", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038911332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079904x3861", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040600148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.93.22.12490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041835884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/hy1101.092970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042478946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08089-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044050224"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-199918060-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047815854", 
          "https://doi.org/10.2165/00044011-199918060-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000242405.68461.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051813961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000242405.68461.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051813961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1440-1681.2003.03911.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052144102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200006223422507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053038763"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.febslet.2004.09.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054735137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.87.2.7980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064324894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circ.106.25.3143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075204771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077945134", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-12", 
    "datePublishedReg": "2007-12-01", 
    "description": "OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care.\nRESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed.\nMAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs).\nRESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE.\nCONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1475-2840-6-12", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031021", 
        "issn": [
          "1475-2840"
        ], 
        "name": "Cardiovascular Diabetology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients", 
    "pagination": "12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c070b3291c4375024196f75880e81cee1b40e443baeb119fe36879fbf8ec1a8d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17407587"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101147637"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1475-2840-6-12"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040398603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1475-2840-6-12", 
      "https://app.dimensions.ai/details/publication/pub.1040398603"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1475-2840-6-12"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'


 

This table displays all metadata directly associated to this object as RDF triples.

313 TRIPLES      21 PREDICATES      89 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1475-2840-6-12 schema:about N03e4cdd7a09243fe9939da582a61cb95
2 N0b57d90a4f6a4cb0b3feaa30d2bde8c7
3 N1c822f9977ec4945a90da0cc0438e684
4 N23651edb2b204444b2d7e3b2bdc400d7
5 N27d52a3e6aba448996ed5adb2cea252d
6 N3b777c641e98445bbe88dc90a04738d5
7 N4c7090a27c4748e6afe24bf62bd1b9b4
8 N4d45b9a445574ec49765465b68b8bea4
9 N63b63e34f02b4688945610d451fb7b1d
10 N6c4fe23c39db4b27b9fcc7ed635f4c62
11 N6d681e97471f4c69bab488092c1caedf
12 N6eeffbf17dbb4260971a55b50fe5851e
13 N6f97778e4719421f829239f43d154c8c
14 N7fb09d0752554358b849865616a015bb
15 N83a758a5e2ab4a11808063206223e5eb
16 N9a5307abe6be4d7491e0ff9eb238d89c
17 Na5ed700fc117435081e5edcfb2898d58
18 Naa749a10b6c54294a8047608dc9c48da
19 Nb0a34335945f496794d86e8704202ca4
20 Nb976cb3ebbc3428c8f8fa60779ba69d9
21 Nd9e8bf459a9b4f27a9773f04a548d69b
22 Ndbf8b0cdbd6a4c1283df53f8306a04de
23 Ndf5691582127489db48ceec59393200f
24 anzsrc-for:11
25 anzsrc-for:1102
26 schema:author N2a27dfadbed9484cbadda96a67f624a3
27 schema:citation sg:pub.10.1007/s00038-004-3063-5
28 sg:pub.10.1007/s001250051268
29 sg:pub.10.1186/1475-2840-4-6
30 sg:pub.10.2165/00003495-199200441-00013
31 sg:pub.10.2165/00044011-199918060-00004
32 sg:pub.10.2165/00044011-200020010-00001
33 https://app.dimensions.ai/details/publication/pub.1077945134
34 https://doi.org/10.1001/jama.288.21.2709
35 https://doi.org/10.1001/jama.288.23.2981
36 https://doi.org/10.1016/j.febslet.2004.09.027
37 https://doi.org/10.1016/s0140-6736(02)08089-3
38 https://doi.org/10.1016/s1262-3636(07)70067-8
39 https://doi.org/10.1046/j.1440-1681.2003.03911.x
40 https://doi.org/10.1056/nejm200006223422507
41 https://doi.org/10.1073/pnas.93.22.12490
42 https://doi.org/10.1097/00004872-199917020-00001
43 https://doi.org/10.1097/00004872-200406000-00024
44 https://doi.org/10.1097/01.hjh.0000133732.24501.9e
45 https://doi.org/10.1097/01.hjh.0000242405.68461.84
46 https://doi.org/10.1111/j.1524-6175.2004.04720.x
47 https://doi.org/10.1146/annurev.nutr.22.010402.102808
48 https://doi.org/10.1146/annurev.nutr.23.011702.073212
49 https://doi.org/10.1161/01.cir.0000080897.52664.94
50 https://doi.org/10.1161/01.cir.0000127955.36250.65
51 https://doi.org/10.1161/01.cir.0000141736.76561.78
52 https://doi.org/10.1161/01.hyp.0000123072.34629.57
53 https://doi.org/10.1161/01.hyp.0000168046.19884.6a
54 https://doi.org/10.1161/01.hyp.0000215181.60228.f7
55 https://doi.org/10.1161/circ.106.25.3143
56 https://doi.org/10.1161/circulationaha.105.169404
57 https://doi.org/10.1161/hy1101.092970
58 https://doi.org/10.1185/030079904x3861
59 https://doi.org/10.1210/jcem.87.2.7980
60 https://doi.org/10.1373/clinchem.2006.067397
61 https://doi.org/10.2337/diacare.24.4.683
62 https://doi.org/10.2337/diacare.26.3.575
63 https://doi.org/10.3317/jraas.2003.026
64 schema:datePublished 2007-12
65 schema:datePublishedReg 2007-12-01
66 schema:description OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. RESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. MAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. CONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.
67 schema:genre research_article
68 schema:inLanguage en
69 schema:isAccessibleForFree true
70 schema:isPartOf N1feeb433b1c54951b93013961a3761c9
71 Na5369461478c4235823e58bf04c8ff24
72 sg:journal.1031021
73 schema:name Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
74 schema:pagination 12
75 schema:productId N379b8548c12e47248c62d7a5a78a59ee
76 N6b42ba61cdcf414eb21cf23c1aa7d6a3
77 Nbca36b1190584f47b5bd2fabba798ad3
78 Nce824da2f68b4d75a20417ca243033f4
79 Nf5ebe200b9e641b38c0b8d05131e4fa6
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040398603
81 https://doi.org/10.1186/1475-2840-6-12
82 schema:sdDatePublished 2019-04-10T20:47
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher Nd8cac321438a47a08bdc26448b9a8030
85 schema:url http://link.springer.com/10.1186%2F1475-2840-6-12
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N03e4cdd7a09243fe9939da582a61cb95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Blood Glucose
91 rdf:type schema:DefinedTerm
92 N0b57d90a4f6a4cb0b3feaa30d2bde8c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Blood Pressure
94 rdf:type schema:DefinedTerm
95 N1c822f9977ec4945a90da0cc0438e684 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Humans
97 rdf:type schema:DefinedTerm
98 N1feeb433b1c54951b93013961a3761c9 schema:volumeNumber 6
99 rdf:type schema:PublicationVolume
100 N205f6c8add4340b1bc62bbdb269992e3 rdf:first sg:person.0752125516.35
101 rdf:rest rdf:nil
102 N23651edb2b204444b2d7e3b2bdc400d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 N27d52a3e6aba448996ed5adb2cea252d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Hydrochlorothiazide
107 rdf:type schema:DefinedTerm
108 N2a27dfadbed9484cbadda96a67f624a3 rdf:first sg:person.0636477725.27
109 rdf:rest N53ecf94e35724fccb028bc5da5ddd22e
110 N379b8548c12e47248c62d7a5a78a59ee schema:name doi
111 schema:value 10.1186/1475-2840-6-12
112 rdf:type schema:PropertyValue
113 N3b777c641e98445bbe88dc90a04738d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Prospective Studies
115 rdf:type schema:DefinedTerm
116 N4c7090a27c4748e6afe24bf62bd1b9b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Biphenyl Compounds
118 rdf:type schema:DefinedTerm
119 N4d45b9a445574ec49765465b68b8bea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Tetrazoles
121 rdf:type schema:DefinedTerm
122 N53ecf94e35724fccb028bc5da5ddd22e rdf:first sg:person.01304431360.27
123 rdf:rest N648b97ea8a5249258768203be4c68af7
124 N63b63e34f02b4688945610d451fb7b1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Cardiovascular Diseases
126 rdf:type schema:DefinedTerm
127 N648b97ea8a5249258768203be4c68af7 rdf:first sg:person.01220266165.99
128 rdf:rest Nd3af35b6c7cc408e89252681cf69e050
129 N6b42ba61cdcf414eb21cf23c1aa7d6a3 schema:name readcube_id
130 schema:value c070b3291c4375024196f75880e81cee1b40e443baeb119fe36879fbf8ec1a8d
131 rdf:type schema:PropertyValue
132 N6c4fe23c39db4b27b9fcc7ed635f4c62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Cholesterol, HDL
134 rdf:type schema:DefinedTerm
135 N6d681e97471f4c69bab488092c1caedf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Risk Factors
137 rdf:type schema:DefinedTerm
138 N6eeffbf17dbb4260971a55b50fe5851e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Aged
140 rdf:type schema:DefinedTerm
141 N6f97778e4719421f829239f43d154c8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Antihypertensive Agents
143 rdf:type schema:DefinedTerm
144 N7fb09d0752554358b849865616a015bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Hypertension
146 rdf:type schema:DefinedTerm
147 N83a758a5e2ab4a11808063206223e5eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Abdominal Fat
149 rdf:type schema:DefinedTerm
150 N9a5307abe6be4d7491e0ff9eb238d89c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Drug Therapy, Combination
152 rdf:type schema:DefinedTerm
153 Na5369461478c4235823e58bf04c8ff24 schema:issueNumber 1
154 rdf:type schema:PublicationIssue
155 Na5ed700fc117435081e5edcfb2898d58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Female
157 rdf:type schema:DefinedTerm
158 Naa749a10b6c54294a8047608dc9c48da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Fasting
160 rdf:type schema:DefinedTerm
161 Nb0a34335945f496794d86e8704202ca4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Metabolic Syndrome
163 rdf:type schema:DefinedTerm
164 Nb976cb3ebbc3428c8f8fa60779ba69d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Cohort Studies
166 rdf:type schema:DefinedTerm
167 Nbca36b1190584f47b5bd2fabba798ad3 schema:name dimensions_id
168 schema:value pub.1040398603
169 rdf:type schema:PropertyValue
170 Nce824da2f68b4d75a20417ca243033f4 schema:name pubmed_id
171 schema:value 17407587
172 rdf:type schema:PropertyValue
173 Nd3af35b6c7cc408e89252681cf69e050 rdf:first sg:person.01205715672.60
174 rdf:rest N205f6c8add4340b1bc62bbdb269992e3
175 Nd8cac321438a47a08bdc26448b9a8030 schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Nd9e8bf459a9b4f27a9773f04a548d69b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Middle Aged
179 rdf:type schema:DefinedTerm
180 Ndbf8b0cdbd6a4c1283df53f8306a04de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Angiotensin II Type 1 Receptor Blockers
182 rdf:type schema:DefinedTerm
183 Ndf5691582127489db48ceec59393200f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Triglycerides
185 rdf:type schema:DefinedTerm
186 Nf5ebe200b9e641b38c0b8d05131e4fa6 schema:name nlm_unique_id
187 schema:value 101147637
188 rdf:type schema:PropertyValue
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
193 schema:name Cardiorespiratory Medicine and Haematology
194 rdf:type schema:DefinedTerm
195 sg:journal.1031021 schema:issn 1475-2840
196 schema:name Cardiovascular Diabetology
197 rdf:type schema:Periodical
198 sg:person.01205715672.60 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
199 schema:familyName Thoenes
200 schema:givenName Martin
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205715672.60
202 rdf:type schema:Person
203 sg:person.01220266165.99 schema:affiliation https://www.grid.ac/institutes/grid.420214.1
204 schema:familyName Paar
205 schema:givenName W Dieter
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220266165.99
207 rdf:type schema:Person
208 sg:person.01304431360.27 schema:affiliation https://www.grid.ac/institutes/grid.4488.0
209 schema:familyName Bramlage
210 schema:givenName Peter
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304431360.27
212 rdf:type schema:Person
213 sg:person.0636477725.27 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
214 schema:familyName Kintscher
215 schema:givenName Ulrich
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636477725.27
217 rdf:type schema:Person
218 sg:person.0752125516.35 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
219 schema:familyName Unger
220 schema:givenName Thomas
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752125516.35
222 rdf:type schema:Person
223 sg:pub.10.1007/s00038-004-3063-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022661411
224 https://doi.org/10.1007/s00038-004-3063-5
225 rdf:type schema:CreativeWork
226 sg:pub.10.1007/s001250051268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001153018
227 https://doi.org/10.1007/s001250051268
228 rdf:type schema:CreativeWork
229 sg:pub.10.1186/1475-2840-4-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018238203
230 https://doi.org/10.1186/1475-2840-4-6
231 rdf:type schema:CreativeWork
232 sg:pub.10.2165/00003495-199200441-00013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010937770
233 https://doi.org/10.2165/00003495-199200441-00013
234 rdf:type schema:CreativeWork
235 sg:pub.10.2165/00044011-199918060-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047815854
236 https://doi.org/10.2165/00044011-199918060-00004
237 rdf:type schema:CreativeWork
238 sg:pub.10.2165/00044011-200020010-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004560003
239 https://doi.org/10.2165/00044011-200020010-00001
240 rdf:type schema:CreativeWork
241 https://app.dimensions.ai/details/publication/pub.1077945134 schema:CreativeWork
242 https://doi.org/10.1001/jama.288.21.2709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009474275
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1001/jama.288.23.2981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016077891
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/j.febslet.2004.09.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054735137
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s0140-6736(02)08089-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044050224
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s1262-3636(07)70067-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014292627
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1046/j.1440-1681.2003.03911.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052144102
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1056/nejm200006223422507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053038763
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1073/pnas.93.22.12490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041835884
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1097/00004872-199917020-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003918995
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1097/00004872-200406000-00024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002454474
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1097/01.hjh.0000133732.24501.9e schema:sameAs https://app.dimensions.ai/details/publication/pub.1030294418
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1097/01.hjh.0000242405.68461.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051813961
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1111/j.1524-6175.2004.04720.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008782891
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1146/annurev.nutr.22.010402.102808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038789731
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1146/annurev.nutr.23.011702.073212 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033009996
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1161/01.cir.0000080897.52664.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010001455
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1161/01.cir.0000127955.36250.65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029448060
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1161/01.cir.0000141736.76561.78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032387441
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1161/01.hyp.0000123072.34629.57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005277791
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1161/01.hyp.0000168046.19884.6a schema:sameAs https://app.dimensions.ai/details/publication/pub.1007193277
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1161/01.hyp.0000215181.60228.f7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038043341
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1161/circ.106.25.3143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075204771
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1161/circulationaha.105.169404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030755840
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1161/hy1101.092970 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042478946
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1185/030079904x3861 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040600148
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1210/jcem.87.2.7980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064324894
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1373/clinchem.2006.067397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038911332
295 rdf:type schema:CreativeWork
296 https://doi.org/10.2337/diacare.24.4.683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005367642
297 rdf:type schema:CreativeWork
298 https://doi.org/10.2337/diacare.26.3.575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009237000
299 rdf:type schema:CreativeWork
300 https://doi.org/10.3317/jraas.2003.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018201506
301 rdf:type schema:CreativeWork
302 https://www.grid.ac/institutes/grid.417924.d schema:alternateName Sanofi (France)
303 schema:name Sanofi-Aventis, Medical Affairs, Paris, France
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.420214.1 schema:alternateName Sanofi (Germany)
306 schema:name Sanofi-Aventis Deutschland GmbH, Medical Affairs CardioVascularThrombosis, Berlin, Germany
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.4488.0 schema:alternateName TU Dresden
309 schema:name Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Germany
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.6363.0 schema:alternateName Charité
312 schema:name Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité, Berlin, Germany
313 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...